New event to create unique synergies between the parallel worlds of large, small molecules and contract services
UBM’s pharma portfolio announced the launch of a new independently branded biopharma event, BioLive, next year in Madrid (9–11 October, 2018 at IFEMA, Feria de Madrid) — specifically for bioprocessing and manufacturing.
The new event has been created after independent research identified a gap in the market for a new global exhibition and content platform that could establish premium-class, global leadership across the entire bio manufacturing value chain.
BioLive will serve as a global hub for both upstream and downstream processing and manufacturing, connecting biotechs, big pharma and service providers including CDMOs and CROs from early stage development to commercial manufacturing and regulatory services.
It will also feature biogeneric and bioinnovator audiences through to manufacturing and laboratory specialists.
Analyst research indicated that running the new event in parallel to its enormous contract services (ICSE) and small molecule (CPhI Worldwide) exhibitions — both currently the world’s largest in their respective areas — would create natural synergies and establish the first truly global hub covering the entire biopharma and pharma supply chains.
“It is a hugely exciting time for the bio industry globally and we expect rapid growth in what is now a maturing supply chain. Independent research showed a dissatisfaction amongst existing options and we have identified that we can provide broader depth in bio manufacturing and processing, whilst capitalising on our collective portfolio strength to bring additional value by combining the small and large molecule worlds together with contract services,” said Rutger Oudejans, Brand Director at UBM.
“It is firstly to provide an ecosystem to bring together the bio development and manufacturing sectors. But it also enables companies and professionals involved across the full pharma value chain of both small and large molecule to learn from eachother and evolve new strategies to overcome the challenges in bio processing and manufacturing.”
Attendees at BioLive will benefit from a mixture of science and technology content — including presentations and conferences on the latest bio innovations and techniques — alongside specialised business development and partnering programmes to help them directly match with the most appropriate partners.
BioLive will help big pharma’s bio divisions and biopharma giants to assess the specific niche services they need, such as analytics and testing. Conversely, the event will empower the small and medium sized bio innovators who want to feed new therapies into the development pipelines of larger companies.
Bio innovators will also be able to look for the external partners they need to push forward their drug development and commercialisation programmes.
Additionally, BioLive will include the producers of specialised bio lab equipment — such as high-performance liquid chromatography — needed for biopharmaceutical research, QC and regulatory submissions.
Alongside the plethora of adjacent industries from reagent suppliers, CROs to equipment, consultancy and service providers from across the whole bio value chain.
There is great potential in bringing the bio community together under the auspices of one new global event — running at the same time as CPhI Worldwide. The launch of BioLive will help accelerate the development of the bio supply chain, improve knowledge exchange and create a more collaborative bio/pharma environment.
Eric Langer, President and Managing Partner at BioPlan Associates, said: “This event has been developed to provide an opportunity for both bio and pharma executives to meet and exchange ideas, and to address key challenges the industry faces, including how to overcome supply chain, processing and manufacturing challenges.”
“The industry needs an effective forum where it can centralise both bio and pharma partners who can now meet different parts of the global bio/pharma industry, especially as the bio manufacturing segment matures. Industry data suggests that biopharma can still learn much from small molecule pharma and that is why this new event could provide unique perspectives that can advance the bio industry.”